Protagonist Therapeutics, Inc.
PRTXDrugs in Pipeline
4
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Open-label rusfertide
Polycythemia Vera
Rusfertide
Polycythemia Vera
PTG-300
Hereditary Hemochromatosis
PN-943
Ulcerative Colitis Chronic Moderate
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Open-label rusfertide | Phase 3 | Polycythemia Vera | - | - |
Rusfertide | Phase 3 | Polycythemia Vera | - | - |
PTG-300 | Phase 2 | Hereditary Hemochromatosis | - | - |
PN-943 | Phase 2 | Ulcerative Colitis Chronic Moderate | - | - |
Polycythemia Vera
3 drugs in this indication
Ulcerative Colitis Chronic Moderate
1 drug in this indication
Hereditary Hemochromatosis
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Protagonist Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in Protagonist Therapeutics, Inc.'s (PRTX) pipeline across Phase 3, Phase 2. Its lead program is Open-label rusfertide (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Protagonist Therapeutics, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Protagonist Therapeutics, Inc. (PRTX) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track PRTX biotech catalysts?→
Add PRTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Protagonist Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.